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A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying 
pentafluorosulfanyl (SF 5) and pentafluoroethyl (C 2F5) substituents: improved 
antiproliferative agents against prostate cancer.   
Fabrizio Pertusati,* ‡ Salvatore Ferla ‡, Marcella Bassetto ‡, Andrea Brancale, Sahar Khandil, 
Andrew D. Westwell and Christopher McGuigan 
School of Pharmacy and Pharmaceutical Sciences, Redwood Building, King Edwards VII Avenue, CF10 
3NB, Cardiff, Wales, UK. 
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Abstract: SAR studies on bicalutamide, enobosarm and enzalutamide analogues, functionalised 
with polyfluorinated groups, is presented. Among the novel bicalutamide and enobosarm 
derivatives synthesised, several displayed significantly improved in vitro anticancer activity, with 
IC50 values in the low micromolar range against four different prostate cancer cell lines (LNCaP, 
VCaP, DU-145 and 22Rv1), showing up to 48-fold increase in comparison with the parent 
structures. In particular, SF5 enobosarm analogues were found to be most potent compounds, full 
AR antagonists and with favourable ADME properties. The most promising compound (48a) was 
evaluated for its in vivo efficacy in PC xenograft mouse model (22Rv1) with results comparable 
to the standard-of-care docetaxel. 
Introduction 
In the recent years, incorporation of fluorine and fluorine-containing groups into organic molecules 
to perturb the chemical, physical and biological properties of the parent compounds has proved 
to be a very successful strategy in drug design.1-6 Fluorine atom in organic molecules, can impart 
a unique set of properties due to the distinctive combination of electronegativity, size and 
lipophilicity.7-9 These factors combined have a substantial impact on molecular conformation of 
the drug, which may affect the binding affinity to the target protein.  For these reasons, organo-
fluorine structures have received and they are still receiving increasing attention in medicinal 
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chemistry,10-15 and currently, fluorine is found in about 20% of pharmaceuticals.13 The 
trifluoromethyl,16-18 difluoromethyl19-22 and fluoromethyl groups23 (in decreasing order)24 are the 
most exploited fluorinated groups in medicinal chemistry. In contrast, polyfluoroalkyl groups have 
been little exploited in medicinal chemistry compared to the above groups.25, 26 However, recent 
years have witnessed an increased use of higher polyfluorinated groups in drug candidate 
molecules. Examples of these are the pentafluoroethyl (C2F5)  and the pentafluorosulfanyl groups 
(SF5).27 The C2F5 group shows a broad synthetic access, whereas incorporation of SF5, group is 
more challenging. The intrinsic difficulty of its introduction into a variety of substrates due to the 
harsh conditions needed has often precluded the investigation of its use in medicinal chemistry. 
Nevertheless, the last few years have witnessed an increased use of this functional group, 
especially in material chemistry, due to the appearance of novel and safe synthetic 
methodologies.28, 29 Nowadays more and more building blocks functionalised with the SF5 group 
are commercially available making the pentafluorosulfanyl group increasingly used even among 
medicinal chemists.30-34 A few reports on drugs functionalised with SF5 and C2F5 have showed an 
improvement in their physiological and / or biological properties compared to the parent drugs.34-
40 The breast cancer therapeutic agent fulvestrant (Faslodex®, Figure.1), is the only approved 
drug containing a C2F5 group. Studies on its mode of action have shown that its unique C-7 side 
chain with a terminal C2F5 group is responsible for the increased metabolic stability during the 
receptor binding.41 In 2017, the first clinical candidate containing a SF5 group (DSM265) reached 
Phase IIa trials for the treatment of malaria (Figure.1).42 During these studies, an aniline ring with 
a 4-SF5 motif provided the optimal balance between parasite activity, metabolic stability, and good 
pharmacokinetic and safety profiles in patients.43 
  
Figure 1: Structure of the anticancer drug Fulvestrant and the antimalarial agent DSM265. 
Introduction of fluorine and polyfluorinated units such as the trifluoromethyl group has been a 
successful strategy in the development of efficacious drugs for the treatment of Prostate Cancer 
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(PC) (Figure 2). PC is one of the major causes of death of men in worldwide.44 The initial treatment 
of PC is often androgen deprivation therapy (ADT). Unfortunately, after an initial response to ADT, 
the vast majority of patients will go on to develop the most aggressive form of this disease called 
castration resistant (CRPC) disease within a median timespan of 2-3 years.45, 46 CRPC still 
depends on androgen stimulation for its growth and as such the use of androgen receptor (AR) 
inhibitors is still useful either alone or in combination with other therapies.47  
  
Figure 2 : Structures of non-steroidal anti-androgens (1-3) and abiraterone acetate (4), drugs 
approved for the treatment of various stages of Prostate Cancer. 
One of the problems associated with the use of bicalutamide, and similar compounds is that their 
prolonged use not only causes resistance but theyir use enhance the tumor growth. Efforts to 
contrast this resistance resulted in the development of novel and high affinity anti-androgens, 
which extended the median survival time of CRPC patients. Molecules such as enzalutamide 
(Xtandi®, MDV3100, 2) and the most recently approved apalutamide (ARN-509, 3, for non-
metastatic PC) and abiraterone acetate (Zytiga® 4) are now extensively used in PC therapy. 
Unfortunately, despite a favorable profile of these drugs, patients with CPRC and those who are 
initially sensitive eventually begin to develop secondary resistance also to these drugs as for 
example reported for enzalutamide.50 Despite the resistance problem, ASCO recommends “men 
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with metastatic CRPC to continue hormone therapy to keep androgen levels low regardless of 
the other treatments used”.51 In this scenario it is evident that the search for more potent agent 
against prostate cancer is still imperative. In our recent communications52, 53 we have 
demonstrated that the introduction of fluorinated groups into selected positions of the aromatic 
rings of the bicalutamide (1) and enzalutamide (2) allowed us to obtain new compounds with 
improved in vitro anti-proliferative activity in the most common PC cell lines. We were the first to 
demonstrate that depending on the position of these fluorinated groups we could convert the 
partially AR agonist enobosarm into a full AR antagonist molecule with the potential to become a 
PC drug.53 Moreover, structure–activity relationship (SAR) studies on bicalutamide-like molecules 
have shown that electron-poor ring A, (e.g bearing CN, NO2 or CF3) is required for a strong ligand–
AR binding.54 These findings prompted us to explore the effects of the polyfluorinated groups SF5 
and C2F5 on the antiproliferative activity of bicalutamide, enobosarm and enzalutamide in PC cell 
lines.  
The SF5 group, considered as a CF3, tert-butyl, halogen, or nitro groups bioisoster,55 is stable 
under physiological conditions56 and possess unique physical and chemical properties such as a 
great electronegativity coupled with an unusual lipophilicity, which might have an impact in the 
activity considering the very hydrophobic environment of the AR binding pocket). SF5 has also a 
different electron density profile (pyramidal for SF5 opposite to spherical for CF3) as well as a 
larger molar volume than CF3 that may be beneficial for biological activity.55 On other hand  the 
C2F5 group is reported to offer similar properties to SF5 such as comparable lipophilicity, while 
slightly less electronegative. It shows also high chemical and metabolic stability with a size 
intermediate between CF3 and tert-butyl. Therefore, selected enobosarm candidates, were also 
functionalised with the bulkier, but electronically similar to CF3, C2F5 group, and evaluated for their 
antiproliferative activity. 
In this article, we would like to report our findings on the synthesis and the biological evaluation 
including antiproliferative activity on four PC cell lines, of SF5 and C2F5 substituted 
bicalutamide/enobosarm and enzalutamide analogues (Figure 3). For selected structures the AR 
antagonist/agonist behaviour as well as the in vitro ADME properties are reported. The lead 
compound was evaluated for its ability to impair tumor growth in PC xenograft mouse model.  
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Figure 3. General structures of the compounds investigated in this study 
Results and discussion 
Chemistry 
Synthesis of SF5-substituted bicalutamide and enobosarm derivatives.  
The synthesis of bicalutamide and enobosarm-based derivatives have been performed according 
to our previously reported synthetic strategy (Scheme 1).57-59 As previously reported by us, 
racemic and R-bicalutamide analogues showed no significant difference in antiproliferative 
activity and as such, all our enobosarm and bicalutamide-derived structures in this article have 
been prepared as racemic mixtures. However, R-Bicalutamide was prepared and included in the 
biological assays as reference. 
Reactions of the appropriate functionalised anilines 6-14 (SF5, CF3, CN, NO2 and their 
combination) with methacryloyl chloride 5 in dimethyl acetamide provided methacrylamides 15-
23 in good yields (77-95%). These compounds in turn were converted into the epoxides 24-32 by 
oxidation with a hydrogen peroxide/trifluoroacetic anhydride mixture in dichloromethane solution 
at room temperature for 24 hours. Opening of the epoxide with sodium phenolates/thiophenolates 
generated by deprotonation with sodium hydride, furnished the desired sulfide/ether derivatives 
33-53. Further oxidation of the thioether derivatives with meta-chloroperbenzoic acid in 
dichloromethane solution provided the bicalutamide derivatives 49-53 in good yields (57-97%) 
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Scheme 1. Synthesis of bicalutamide ( 33-39,49-53) and enobosarm analogues ( 40-48)  
 
Reagents and conditions: (a) Anilines 6-14 (3.4 mmol scale), 5 (8 equiv.), DMA, rt, 3h; (b) 15-
23, H2O2 (4 equiv.)/(CF3CO)2O (5 equiv.), DCM, rt, 24h; (c) NaH (1.2 equiv.), 24-32 (1.2 equiv.), 
ArXH (a-p), (1.1 equiv. ), THF, rt, 24h; (d) m-CPBA (1.4 equiv.), DCM, rt, 4-6h. 
Synthesis of SF5 substituted enzalutamide derivatives  
Enzalutamide analogues bearing SF5 group either on B or A ring, were synthesised following two 
different procedures, both derived by appropriate modification of reported methodologies.60 
Compounds 65-68 a,b and 69-70d-e  were synthesised according to a three-step literature 
procedure highlighted in Scheme 2.61 Briefly, anilines 6-11 were converted into the corresponding 
isothiocyanates 54-59 by treatment with thiophosgene in dichloromethane solution in presence of 
sodium bicarbonate. These intermediates were successively reacted with amino-cyanide 61-64, 
(in turn prepared from anilines 10-12 and 60 via Strecker reaction), to obtain final enzalutamide 
analogues 65-68 a-b and 69-70d-e. We were also interested in keeping the enzalutamide B ring 
intact while introducing the pentafluorosulfanyl group on the A ring. The synthesis of these 
compounds (75a and b) was accomplished by a literature route reported (Scheme 3).62 Ullmann 
type reaction between 4-bromo-2-fluoro-N-methylbenzamide 72 (prepared from the 
corresponding acid 71) and 2-aminoisobutyric acid, catalysed by copper chloride, afforded the 
functionalized aniline 73 in 67% yield. This was converted into the corresponding methyl ester 74 
(methyl iodide, potassium carbonate, in a water/dimethylformamide mixture), which was 
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subsequently cyclised into the desired enzalutamide derivatives 75a-b with pentafluorosulfanyl 
anilines 58 and 59 in hot dimethylsulfoxide/isopropyl acetate mixture for 14 hours. 
Scheme 2. Synthesis of enzalutamide derivatives 65-68a-b and 69-70d-e.61  
  
Reagents and conditions: a) 6-11, CSCl2 (1.5-2 equiv.), NaHCO3 (4.1 equiv.), H2O, DCM, rt, 
24h; b) TMSCN (5.2 equiv.), acetone, 80 °C, 12 h; c) 54-59 (1.0 mmol), 61-64 (0.84 mmol) DMF, 
rt, 48 h, then 2N HCl (3 mL), MeOH (10 mL), reflux, 6 h. 
Scheme 3. Synthesis of pentafluorosulfanyl enzalutamide derivatives 75a-b.62 
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Reagents and conditions: a) SOCl2, iPAc, DMF, 72 °C, 4 h; b) MeNH2, DMF, rt, 15 min; c) 2-
aminoisobutyric acid, K2CO3, CuCl, 2-acetylcyclohexanone, DMF, H2O, 105 °C, 14 h; d) MeI, 
K2CO3, H2O, DMF, 40 °C, 1h; e) 58-59, DMSO, iPAc, 84 °C, 14 h. 
Synthesis of pentafluoroethyl bicalutamides and enobosarms. 
As part of our interest in exploring the use of polyfluorinated groups in bicalutamide and 
enobosarm series, we then moved to investigate the effect of the pentafluoroethyl functional group 
(C2F5), on the anticancer activity of these new derivatives. For the synthesis of these derivatives, 
we envisaged that an introduction of the desired fluorinated group at the late stage of the synthetic 
pathway (ideally in the last step) would be the best approach. In the recent years, a great deal of 
research has been devoted to the introduction of fluoroalkyl group into aromatic rings. Introduction 
of pentafluoroethyl group onto aromatic compounds have been subjected to a deep investigation 
and several methods are available in literature, mainly by means of organometallic reagents. 
These methodologies often require the in-situ preparation of the pentafluoethyl-metal reagent63-65 
high temperature (1κ0 ˚C),63 and careful control of  reaction conditions. To avoid these problems, 
we looked at the work of Hartwig group who have developed a copper-based reagent 
(pentafluoroethylator®) capable of replacing aromatic iodide or bromide with a CF3 or a C2F5 
groups under relatively mild conditions.66, 67 When we attempted the pentafluorethylation of 
compounds  46o, 48o,p, (see Scheme 1), the reaction worked very well and the desired 
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polyfluorinated derivatives, 77-79 were obtained in good yields after chromatographic separation 
on silica gel (Scheme 4).  
Scheme 4. Synthesis of enobosarm ’s pentafluoroethyl derivatives via 
pentafluoroethylation of iodides 46o, 48o, 48p. 
 
Reagents and conditions: a) Cu(Phen)CF2CF3 76 (2 equiv.), DMF, 50 ˚C, 24 h. 
In our previous studies,53 we demonstrated that Enobosarm analogues with the bis-3,5-CF3 motif 
on the ring B were quite active in the antiproliferative assay. We were then interested into 
investigate if the introduction of the C2F5 functionality on ring A of these derivatives could further 
improve their antiproliferative activity. 
However, the synthetic approach proposed in Scheme 1 was unsuccessful for the synthesis these 
derivatives. In particular, when we attempted the oxidation of 3-iodo alkene 22 with the mixture of 
trifluoroacetic anhydride and hydrogen peroxide, we were only able to observe trace of the desired 
product 31 in a complex mixture with other unidentified product likely derived from the formation 
of hypervalent iodine compounds like bis(trifluoroacetoxy)iodoarene (Scheme 5A).68 In addition, 
the presence of the highly electronegative trifluoromethyl group in the ortho position of anilines 8 
and 9 made these compounds scarcely reactive, and low yields of the acrylamides 17, 18 and 
epoxides 26, 27 were obtained. We envisaged that this low reactivity would have been even more 
severe in the case of a C2F5 group in this position. 
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Scheme 5. A) Unsuccessful epoxidation of methacrylamide 22; B) synthesis of compounds 83 
and 82 via pentafluoroethylation of 22.  
 
Reagents and conditions: a) 76 (2 equiv.), DMF, 50˚C, 4κh; b) H2O2 (4 equiv.)/(CF3CO)2O (5 
equiv.), DCM, rt, 24h; (c) NaH (1.2 equiv.) 3,5-bis-trifluoromethyl thiophenol (1.2 equiv.), THF, rt, 
24h; d) NaH (1.2 equiv.) 3,5-bis-trifluoromethyl phenol (1.2 equiv.), THF, rt, 24 h. 
We therefore decided to attempt the pentafluorethylation directly on compound 22. When a dry 
DMF solution of 22 was then treated under argon with pentafluoroethylator 76 (2 equiv.) at 55 ˚C 
for 48 hours, the desired pentafluoroethyl methacryl amide 80 was obtained in quantitative yield. 
Epoxidation with trifluoroacetic anhydride and hydrogen peroxide proceeded smoothly affording 
pentafluoroethyl epoxide 81 which was then coupled with 3,5-bis-trifluoromethyl thiophenol and 
3,5-bis-trifluoromethyl phenol to afford compounds 83 and 82 in 27% and 36% yield respectively. 
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Biological Evaluation  
In vitro 2D monolayer antiproliferative assay. 
All newly synthesised compounds were evaluated for their antiproliferative effect in an in vitro 2D 
monolayer assay in four human prostate cancer cell lines (LNCaP, 22Rv1, VCaP, and DU145). 
LNCaP, VCaP and 22Rv1 exhibit androgen sensitivity, whereas DU145 was selected as 
hormone-insensitive cell line. 
Vcap cell line was selected because they show positive response for androgen sensitivity with 
wild-type AR mRNA/protein, and expresses PSA mRNA/ protein as well.69 To establish if our 
compounds are effective also on cells with mutated AR, we selected LNcaP cell line that express 
endogenous T877A mutation70, 71 in the AR coding sequence. Finally, 22Rv1 cell line was selected 
because of endogenously expressed AR splice variants. These have been identified as one of 
the main players in hormone refractory tumor progression.72 Two such variants have been 
identified as specifically a full length isoform with an exon 3 duplication and a C terminal domain 
truncations with aberrant exon 2b expression.73 
The antiproliferative activity (absolute IC50 in µM) of the most active compounds are reported in 
table 1 for the bicalutamide/enobosarm series and in table 2 for the enzalutamide series including 
also the antiproliferative activities of four reference compounds (racemic bicalutamide 1 and its 
R- isomer74, enzalutamide 2, enobosarm 40j), which appeared consistent with previous reported 
data for these specific cell lines (see supporting information for the complete table of IC50s). 
Table 1. Antiproliferative activity of selected polyfluorinated bicalutamide and enobosarm 
derivatives in four prostate cancer cell lines. 
E try Cpd 
 
X = O E o osar  derivatives 
X = SO  Bi aluta ide derivatives 
  R A i g  X A  B i g  A solute IC  µM  a 
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     VCap LN ap Rv  Du-  
 f -SF  O -CF  .  .  .  .  
 a , -CF  O -SF  .  .  .  .  
  -SF  O , -CF  .  .   .  
  , -CF  O -C F  .  .  .  .  
  -SF  O , -CF  .  .  .  .  
  , -CF  O -SF  .  .  .  .  
  -NO , -CF  O -SF  .  .  .  .  
  -C F  S , -CF  .  .  .  .  
  -CF  O -C F  .  .  .  .  
  , -CF  O -C F  .  .  .  .  
 J -CN, -CF  O -CN .  .  .  .  
  -CN, -CF  SO  -F .  .  .  .  
 R-  -CN, -CF  SO  -F .  .  .  .  
a All data are mean values from at least triplicate experiments, with standard deviations of ± 10% 
of the value quoted unless otherwise stated (mean value ± standard deviations). 
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Almost all new derivatives performed better than bicalutamide, showing concentration dependent 
activity in all four PC in vitro models. It is possible to appreciate that the best linkers between the 
two portions of the molecule contain either a sulfur or an oxygen atom. When the sulfur was 
oxidized to the corresponding sulfoxide (or sulfone) a general loss of activity was observed. This 
is consistent with what has been previously observed with other bicalutamide derivatives.60, 75 In 
general, the pentafluorosulfanyl group is slightly more efficient in reducing the IC50 when 
compared with the pentafluoroethyl moiety except when present in the para position of ring B and 
ring A is functionalised with a 3,5-bistrifluoromethyl moiety (Table 1, entry 4). However, it is 
important to remark that both polyfluorinated functional groups are more effective than fluorine of 
CF3 groups. In terms of ring substitution, from our data, it seems that the SF5 group is very 
effective when it is located in the para position of ring A (Table 1, entries 1 and 3) and B (Table 
1, entry 2). Compound 44f (4-SF5 on ring A and 2-CF3 on ring B) is more potent than the 
compound 45f (full table on SI) with the same substitution pattern on ring B (2-CF3) but with the 
SF5 on ring A moved to the meta position (table 1). However, when the 3,5-bis CF3 motif is present 
on either ring A or B the position of the SF5 (either ortho or meta) on the other ring seem to be not 
important. Indeed, compounds 48a and 48b (table 1 entry 2 vs 6) do shows the same activities 
except in LNCaP cell where 48a seem to perform better. In the pentafluoroethyl series it is clear 
from the data of table 1 that p-C2F5 in the B ring is very effective for the antiproliferative activity. 
When the ring A is substituted with the 3,5-bis-trifluoromethyl moiety, moving the pentafluoroethyl 
moiety from the 4-position to the 3-position resulted in the reduction of activity (Table 1 entries 4 
vs 10).  
Considering the antiproliferative results across the four different cell lines, the new compounds 
showed significant activity also on androgen-insensitive DU-145 cells with IC50 values for most 
compounds higher in this cell line than in the other three, suggesting the presence of a potential 
off-target effect, besides the canonical anti-androgen mechanism. Interestingly, some studies 
have demonstrated that even DU-145 and PC3 cell lines are expressing significant levels of AR 
protein, although at a lower level than LnCaP cell line.76 In addition, DU-145 cell line usually 
express NF-kB, a transcription factor involved in prostate cancer progression.77 It seem plausible 
to speculate that our molecules are either blocking the AR expressed by the DU-145 cells or are 
somewhat able to target other pathways such as the expression of NF-kB.  
Within the enzalutamide series only three derivatives (67a, 70e and 67b) showed a better activity 
than enzalutamide itself (Table 2) in LnCaP cell line. Unfortunately, in these series, the solubility 
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of these polyfluorinated compounds posed a serious limitation in their anti-proliferative evaluation 
(See SI for complete table of the antiproliferative data). 
Table 2. Antiproliferative activity of selected polyfluorinated enzalutamide derivatives in four 
prostate cancer cell lines. 
a All data are mean values from at least triplicate experiments, with standard deviations of ± 10% of the 
value quoted unless otherwise stated (mean value ± standard deviations). 
During the preparation of this manuscript, a similar study appeared in the literature where 
pentafluorosulfanyl substituted enzalutamide analogues, were evaluated for their in vitro efficacy 
in LnCaP cell lines as well as for their AR antagonism.78 Similar to our findings, the antiproliferative 
activity of these derivatives, although structurally different from ours, was found similar to 
enzalutamide. In addition, antagonism behaviour was proved for these compounds. 
Entry Cpd 
   
  R A i g  A  B i g  A solute IC  µM a 
    VCap LN ap Rv  Du-  
 a -CN, -CF  -SF   .  .   
 e  -SF  -CF  .  ND ND .  
   -CN, -CF  -SF  .  ND ND .  
  
Enzalutamide 
-CN, -CF  -F, 
-CONHMe 
.  .  .  .  
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Agonist-antagonism assay 
Once established the efficacy of these new derivatives in the antiproliferative assay, we 
progressed to evaluate their AR antagonist activity. 
Among all the derivatives prepared, compound 44f with a SF5 group in the A ring and our best 
analogue in terms of antiproliferative activity, along with compound 41b, bearing the 
pentafluorosulfanyl substituent on the B ring were investigated in an agonist/antagonist assay 
(Figure 4). We used the GeneBLAzer® beta lactamase reporter technology adapted to the nuclear 
receptor, to asses if these compounds are AR antagonists. Indeed, we observed that both 
compounds behave as full AR antagonists. It is worth noting that introduction of the SF5 motif 
leads to the switch of the enobosarm scaffold from partial agonist to full antagonist of the AR 
receptor, as also previously observed by us with other fluorinated groups.53, 60 Figure 4 below 
shows the dose response curve for enobosarm 40j (A) 41b (B) and  44f (C). Table 3 collects the 
IC50 values, the antagonistic and agonistic mean effect, expressed as percentage, for the three 
compounds in the same assay. This result is of great significance for the future development of 
AR antagonist and ultimately for the treatment of PC condition. 
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 Figure 4.  Dose Response curve (at 10 different concentrations, max 10 µM) for the antagonist 
assay for Enobosarm 40j (A) and compounds 41b (B), 44f (C). The mean value from the two 
experiments has been plotted in a graph log (antagonist) ([M]) against % of inhibition. 
 
Table 3.  AR antagonistic and agonistic activity of enobosarm (40j), compounds 41b, 44f and, as 
comparison, Bicalutamide (1). 
Cpds 
Antagonistic 
(mean % inhibition) 1,2,3 
IC50 (µM)1,3 
Agonistic 
(mean % activation) 1,4 
40j 59 0.036 26 
41b 90 0.540 2 
44f 93 1.810 -3 
1 83 0.490 5 
1Data presented are the means from duplicate experiments; 2Compounds were considered full 
antagonists if at 10µM the reduction of R1881 (standard AR antagonist) effect was greater than 
80%; 3Data from compounds tested at 10 different concentrations; 4Data from compounds tested 
at single (10 µM) concentration in absence of R1881. 
 
In vitro Absorption, Distribution, Metabolism, and Excretion (ADME) screening. 
 Compounds 44f, 41b and 48a were evaluated for their metabolic stability, binding to protein and 
cardiotoxicity (Table 4). First the tested compounds were incubated for 45 min with pooled liver 
microsomes, and the intrinsic clearance (CLint) and half-life (t1/2) values were calculated based on 
5 time points for a maximum of 45 minutes (Table 4). All compounds examined, except 44f (which 
shows a medium CLint value and short half-life), have low intrinsic clearance in liver microsome 
and long half-lives (~7.5 hours). In particular, compounds 48a, 41b, showed CLint values below 6 
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L/min/mg microsomal protein, suggesting that these compounds will undergo much slower rates 
of hepatic metabolism in vivo. In addition, compounds 48a and 41b showed a metabolic stability 
greater than bicalutamide confirming the reported bio-stability of the pentafluorosulfanyl motif.79 
All the selected candidates showed plasma protein binding greater than 91%. Our most active 
compound 44f, showed a 98.6% protein binding very similar to the bicalutamide value (96%).80 
The least bound to plasma protein was compound 48a (91%). Moreover, all tested compounds 
lacked significant hERG inhibition in the patch-clamp assay (at 6 different concentrations). In 
particular, the most active compounds in antiproliferative assay, 44f and 48a showed a mean 
hERG inhibition of 26.3% and 13.4% respectively at 25 µM. The IC50 calculated over 6-different 
concentrations were all above 25 µM showing a satisfactory degree of safety for these derivatives. 
Table 4. Metabolic stability in pooled liver microsomes, plasma protein binding and 
cardiotoxicity results of selected compounds. 
a µL/min/mg protein, from quadruplicate assay; b Data expressed as mean values from duplicate 
experiments; c data at 25 µM: Weak or no inhibition from quadruplicate experiments if IC50 >10µM; 
d From literature data;80 e Not Determined. 
In vivo efficacy evaluation in 22Rv1 prostate cancer model. 
 With the ADME data in hand we decided to evaluate one of our best performing 
pentafluorosulfanyl derivatives in an in vivo efficacy xenograft model in mice to assay their ability 
to impair the growth of prostate tumour in comparison to the standard-of-care docetaxel. Among 
Co p CLi ta,  T /  i .  PPB % ou d  hERG % ea  i hi itio   
f .  .  .  .  
a .   .  .  
 .   .  .  
R -  .   d NDe 
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the most active bicalutamide/enobosarm series in the antiproliferative activity, compound 48a, 
although slightly less potent than compound 44f was selected for in vivo evaluation because its 
longer t1/2 value, and lower plasma protein binding and because it was one of the better performing 
compound in our previously published results on bis-CF3 analogues.53 
At first, the tolerability of 48a were tested in nude, non-tumour bearing mice with the maximum 
tolerated dose (MTD) established at 100 mg/Kg and then used later for the xenograft experiment. 
Standard-of-care docetaxel was instead given at a dose level of 15mg/Kg. (Table 5). 
Table 5. Summary of the in vivo efficacy experiments Tumor Model PRXF 22Rv1 
n/a, not applicable; n.r., not reached (i.e. group median RTVs always < 200% / 400%); Efficacy rating: 
++++, T/C < 5%, +++, T/C: 5 - < 10%; ++, T/C: 10 - <25%; +, T/C: 25 - <50%; +/-, T/C : 50-65%; -, T/C  
65%; a Vehicle for 48a and the control group: 10% EtOH, 10% Cremophor EL, 5% dextrose; vehicle for 
docetaxel, 0.9% Saline; b Minimum T/C values are calculated based on median values; c Tumor volume 
doubling time; d Tumor volume quadrupling time; e Docetaxel was used as positive control, while  DMSO 
(vehicle) was used as negative control. 
Then, in vivo efficacy data were obtained selecting 22Rv1 cells to perform this study. Mice were 
injected in the hind flank with tissue culture 22Rv1 cells. Once enough tumors have formed, the 
tumor-bearing mice were randomised into groups and therapy with 48a and docetaxel were 
performed for 4 weeks. Treatment with the investigational compound was given as 16-18 daily 
intraperitoneal (i.p.) doses, whereas docetaxel was given as three weekly intravenous (i.v.) 
The ap a Dose Level 
[ g/kg/da ] 
S hedule 
[dosi g 
Da s] 
Route Mi i u  T/C [%] 
Da  
Effi a  
Rati g 
Td 
[Da s]  
T  
[Da s]d 
Vehi lee  
l/kg/day 
-  i.p. /a /a .  .  
a  -  i.p. .   + .  .  
Do eta ele  , ,  i.v. .   ++ .  .  
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treatments. The treatment period was followed by an observation period until day 40 for 48a group 
and until day 49 in the docetaxel group. The first day of dosing was either the day of randomisation 
(day 0) or the following day (day 1). Anti-tumor efficacy was evaluated as inhibition of tumor 
growth represented by minimum T/C (treated to control) value based on group median relative 
tumor volumes (RTVs) in test and control groups (see SI for the pertinent plot). The body weight 
was also recorded to assess the animal’s tolerance of the compound. The group receiving 
treatment with 48a was compared to the docetaxel and to the control groups. The highest anti-
tumor efficacy was observed in the docetaxel-treated group with a minimum T/C value of 22.4%. 
Compound 48a displayed moderate anti-tumor efficacy with a minimum T/C value of 43.9%. 
(Figure 5) Statistical significance was observed for both docetaxel and compound 48a in 
comparison to the vehicle control group. 
Figure 5.  Efficacy of compound 48a and docetaxel in R22v1 xerograph mice model. 
 
Minimum T/C values for the two groups are shown. As a turning point, a minimum T/C value of 65% (upper limit for borderline anti-tumor efficacy) was 
chosen.  
 
As it can be appreciated by the figure 6A that in the first 10 days of administration, compound 48a 
was able to better control the absolute volume tumor growth with respect to Docetaxel which 
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become more effective as the time progress to 20 days.Treatment with 48a was well-tolerated 
with adjusted survival rates of 100% and no group median body weight losses (BWLs, Figure 6B). 
A severe BWL of 19.8% was recorded in the docetaxel-treated group, although the adjusted 
survival rate was 100%.  
 
Figure 6 . Plot of medians absolute (A) tumor volume and (B) body weight for 48a and docetaxel 
as function of time. 
 
Conclusions 
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In summary, we have demonstrated that functionalisation of bicalutamide and enobosarm scaffold 
with pentafluorosulfanyl and pentafluoroethyl functionality, lead to the development of potent 
antiproliferative agents against prostate cancer in in vitro models. The IC50 for the majority of the 
newly prepared molecules were about 48-times better than the parent drugs. Among the 
compounds with improved anticancer activity, enobosarm analogues performed better with 
respect to their bicalutamide analogues, pointing out that a less bulky linker (compared to SO2) 
between ring A and B lead to a better activity.  
Overall SF5 structures displayed the best in vitro anticancer activity, together with AR full 
antagonism (a key requirement for a drug against prostate cancer) and ADME properties. One of 
the most active compounds (48a) showed also some efficacy in in vivo xenograft experiment, 
although its activity was lower than the standard of care docetaxel. Pleasingly, (48a) was better 
tolerated with respect to docetaxel as evidenced by the lack of body weight lost in the treated 
mice. Pentafluoroethyl derivatives also showed an excellent improvement of the antiproliferative 
activity of the parent compound. 
In contrast, SF5-functionalised Enzalutamides were hampered by low solubility that precluded 
their full evaluation in animal model, although one derivative (67a) showed an improved 
antiproliferative activity (in vitro) with respect to enzalutamide. Altogether, our results are 
indicative of the fact that both SF5 and C2F5 are indeed two functionalities that can be used in 
place of the trifluoromethyl group and exploited for the design of drug-like molecules.  
Having established in this work that the in vitro anticancer activity can be extensively improved, 
for a successful progression of these derivatives to clinical studies, further evaluation of their 
biological properties (PC protein expression, inhibition of AR-mediated gene transcription, 
quantitative AR binding assay) needs to be addressed. These experiments are currently 
underway in our laboratories and will be reported in due course. 
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Experimental 
General Chemistry methods 
All solvents and reagents were used as obtained from commercial sources unless 
otherwise indicated. All reactions were performed under a nitrogen atmosphere. The 1H 
and 13C NMR spectra were recorded on a Varian spectrometer operating at 500 MHz for 
1H and 125 MHz for 13C. Deuterated chloroform was used as the solvent for NMR 
experiments, unless otherwise stated. 1H chemical shifts values (δ) are referenced to the 
residual nondeuterated components of the NMR solvents (δ = 7.26 ppm for CHCl3, etc.). 
The 13C chemical shifts (δ) are referenced to CDCl3 (central peak, δ = 77.0 ppm). 
Fluorine chemical shifts are referenced to CFCl3. Mass spectra were measured in positive 
mode electrospray ionization (ESI). TLC was performed on silica gel 60 F254 plastic 
sheets. Column chromatography was performed using silica gel (35–75 mesh) or on an 
Isolera Biotage system. Purity of prepared compounds was determined by HPLC-UV 
analysis (Thermo HPLC connected with UV detector). The purity of all final compounds 
was determined to be >λ5% by RP-HPLC using the eluents water (eluent A), acetonitrile 
(eluent B), and the following conditionsμ Varian Pursuit XS, 4.6 mm × 150 mm, 5.0 m, 
1.0 mL/min, gradient 30 min 10% → 100% eluent B in eluent A (method 1). HRMS were 
acquire on a Waters XEVO-27-Jun-201λ G2XSQTOF instrument under electrospray 
condition in both positive and negative modes. 
Synthetic Procedures 
General method for the preparation of intermediates 15-23, 80 
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Methacryloyl chloride 5 (2.63 mL, 27.16 mmol) was added over the course of 10 minutes 
to a stirring solution of the different aniline 6-14 (3.4 mmol) in N,N-dimethylacetamide (14 
mL) at r.t. for 3 h or o.n. After the reaction was complete, the mixture was diluted with 
ethyl acetate (100 mL), extracted with sat. aq. NaHCO3 solution (3x25 mL) and with cold 
brine (4x50 mL). The organic layer was dried over Na2SO4 and the solvent vas removed 
at reduced pressure. The crude residue was purified by flash column chromatography.  
N-(4-(Pentafluorosulfanyl)phenyl)methacrylamide 19 
Purified by flash column chromatography eluting with n-hexane-EtOAc 100μ0 v/v 
increasing to n-hexane-EtOAc κ0μ20 v/v. Obtained in λλ% yield as a white solid. 1H NMR 
(CDCl3), μ 7.74 (d, J = λ.2 Hz, 2H), 7.70-7.6κ (m, 3H), 5.κ4 (s, 1H), 5.56-5.55 (m, 1H), 
2.0λ (m, 3H). 1λF NMR (CDCl3), μ κ5.3 (quintet, J = 151.1 Hz, 1F), 63.5 (d, J = 151.1 Hz, 
4F). 13C NMR (CDCl3), μ 166.7, 140.2 (m), 127.0 (m), 120.κ, 11λ.1, 103.λ, κ0.7, 30.1, 
1κ.6. 
N-(3-iodophenyl)methacrylamide 22  
Purified by flash column chromatography eluting with n-hexane-EtOAc 100μ0 v/v 
increasing to n-hexane-EtOAc λ0μ10 v/v. Obtained in 60% yield as a white solid. 1H NMR 
(500 MHz, CDCl3) δ κ.00 (s, 1H, NH), 7.57 (ddd, J  = 0.7, 2.0, κ.2 Hz, 1H), 7.4κ (ddd, J  
= 1.0, 1.5, 7.λ Hz, 1H), 7.0κ (t, J  = κ.0 Hz, 1H), 5.κ1 (s, 1H), 5.51 (d, J  = 1.4 Hz, 1H), 
2.0κ (d, J  = 0.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 166.50, 140.65, 13κ.λ0, 133.45, 
130.47, 12κ.72, 120.21, 11λ.21, 103.λλ, λ4.0κ, κ0.κ1, 30.11, 24.1κ, 1κ.46. 
N-(3,5-bis(Trifluoromethyl)phenyl)methacrylamide 23 
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Purified by flash column chromatography eluting with n-hexane-EtOAc 100μ0 v/v 
increasing to n-hexane-EtOAc λ0μ10 v/v. Obtained in λλ% yield as a white solid. 1H NMR 
(CDCl3), μ κ.11 (s, 2H), 7.76 (bs, 1H), 7 1H), 5.κ7 (d, J = 1.1 Hz), 5.5λ (m, 1H), 2.1 (s, 
3H). 1λF NMR (CDCl3), μ -63.0 (s, 3F). 13C NMR (CDCl3), μ 166.6, 140.2 (q, J  = 33.6 
Hz), 13λ.2, 137.5 (q, J  = 272.κ Hz), 121.0, 117.6 (m), 1κ.6. 
Preparation of N-(3-pentafluoroethyl)phenyl)methacrylamide 80  
A solution of iodide 22 (0.κ g, 2.κ mmol), and (1, 1, 2, 2, 2- Pentafluoroethyl) (1, 10-
phenanthroline- N1, N10)-copper (Pentafluoroethylator®, 5.6 mmol, 2 equiv) in dry 
DMF where heated at 50 ˚C for 4κ hours. After this period the mixture was cooled at room 
temperature and diluted with diethyl ether and the orange solution filtered through a pad 
of celite. The pad was washed with diethyl ether and the combined organic were washed 
with 2M HCl (2x 10 mL) sat NaHCO3 (2x 10 mL) dried and evaporated. The residue was 
pure enough (λ0%) to be used in the next step.  
1H NMR (500 MHz, CDCl3) δ 7.κ5 (t, J  = 12.0 Hz, 2H), 7.65 (s, 1H), 7.50 (t, J  = κ.0 Hz, 
1H), 7.3κ (d, J  = 7.κ Hz, 1H), 5.κ5 (s, 1H), 5.55 (d, J  = 1.4 Hz, 1H), 2.10 (s, 3H). 1λF 
NMR (CDCl3), μ -κ4.63 (s), -117.01 (br s); MS [ESI, m/z]μ 302.05 [M+Na]. 
 
General method for the preparation of intermediates 24-32 
To a stirred solution of the different intermediate 15-23 (3 mmol) in DCM (7 mL) was 
added 30% hydrogen peroxide (3.6 mL, 32.03 mmol). The reaction mixture was put in a 
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water bath at r.t. and trifluoroacetic anhydride (3.7 mL, 26.7 mmol) was added slowly to 
the mixture, which was then stirred for 24 h. The reaction mixture was transferred to a 
separating funnel using DCM (30 mL). The organic layer was washed with distilled water 
(20 mL), sat. aq. Na2S2O3 (4x20 mL), sat. aq. NaHCO3 (3x20 mL) and brine (20 mL), 
dried over Na2SO4 and concentrated at reduced pressure. These intermediates were 
usually of good purity (λ0%) to be used in the next step without further purification. When 
necessary, column chromatography (EtOAc/Hexane, silica gel) or preparative TLC were 
used to purify the compounds. 
N-(4-(pentafluorosulfanyl)phenyl)-2-Methyloxirane-2-carboxamide 28 
Obtained in 73% yield as a white wax. 1H NMR (CDCl3), μ κ.32 (bs, 1H), κ.03-κ.02 (m, 
1H), 7.72-7.70 (m, 1H), 7.52-7.4λ (m, 1H), 7.44-7.3λ (m, 1H), 3.01 (d, J = 4.2 Hz, 1H), 
2.λ7 (d, 4,κ Hz, 1H), 1.67 (s, 3H). 1λF NMR (CDCl3), μ κ5.1 (quintet, J = 151.1 Hz, 1F), 
63.0 (d, J = 151.1 Hz, 4F). 13C NMR (CDCl3), μ 16λ.0, 154.0 (p, J = 1κ.4 Hz), 137.6, 
12λ.2, 122.6, 121.λ (p, J  = 4.κ Hz), 117.3, 67.6, 56.6, 16.6; MS [ESI, m/z]μ 326.2 [M+Na]. 
N-(3-(pentafluorosulfanylphenyl)-2-Methyloxirane-2-carboxamide 29 
Obtained in 72% yield as a white solid. 1H NMR (CDCl3), μ κ.05-7.λλ (m, 1H), 7.κ2-
7.77 (m, 1H), 7.72 (bs, 1H), 7.55-7.50 (m, 1H), 7.4κ-7.40 (m, 1H), 5.κ5 (s, 1H), 5.55 (m, 
1H), 2.0λ (m, 3H). 1λF NMR (CDCl3), μ κ3.λ6 (quintet, J = 151.2 Hz, 1F), 62.62 (d, J = 
151.2 Hz, 4F). 13C NMR (CDCl3), μ 166.7, 140.4 (p, J = 1κ.1 Hz), 13κ.1, 12λ.2, 122.λ, 
121.7 (p, J = 4.4 Hz), 120.6, 117.6 (p, J  = 4.5Hz), 60.4, 1κ.6. 
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    N-(3,5-bis(Trifluoromethylphenyl)-2-methyloxirane-2-carboxamide 32     
Obtained in κ2% yield as a white solid. 1H NMR (CDCl3), μ κ.35 (bs, 1H), κ.07 (s, 2H), 
7.64 (s, 1H), 3.02 (m, 2H), 1.71 (s, 3H). 1λF NMR (CDCl3), μ -63.1 (s, 3F). 13C NMR 
(CDCl3), : 16λ.0, 13κ.4, 132.6 (m), 11λ.3, 117.κ (m), 56.6, 16.7. 
 
General method for the preparation of compounds 33-48 
To a mixture of NaH (60% in mineral oil, 0.050 g, 1.23 mmol) in anhydrous THF (2 mL) 
at 0 °C under Ar atmosphere was added a solution of the differently substituted phenol or 
thiophenol (1.11 mmol) in 1 mL of anhydrous THF. This mixture was stirred at r.t. for 20 
minutes. A solution of the different intermediate 24-32 (0.74 mmol) in anhydrous THF (3 
mL) was added slowly. The reaction mixture was stirred at r.t. overnight. The mixture was 
then diluted with ethyl acetate (30 mL), washed with brine (15 mL), water (30 mL), and 
dried over Na2SO4 and concentrated under vacuum. The crude residue was purified by 
flash column chromatography or via Biotage Isolera 1. 
N-(4-(pentafluorosulfanyl)phenyl)-3-(2-(trifluoromethyl)phenoxy)-2-Hydroxy-2-methyl 
propanamide 44f 
Purified by flash column chromatography eluting with n-hexane/EtOAc 100:0 v/v increasing to n-
hexane/EtOAc 70:30 v/v. Obtained in 59% yield as a white solid. 1H NMR (CDCl3), : 8.84 (bs, 
1H), 7.75 (d, J = 9.2 Hz, 2H), 7.69 (d, J = 9.2 Hz, 2H), 7.61-7.59 (m, 1H), 7.56-7.53 (m, 1H), 7.12-
7.09 (m, 1H), 7.03 (d, J = 8.3 Hz, 1H), 4.48 (d, J = 8.7 Hz, 1H), 4.12 (d, J = 8.7 Hz, 1H), 3.55 (s, 
1H), 1.64 (s, 3H). 19F NMR (CDCl3), : 84.8 (quintet, J = 150.1 Hz, 1F), 62.9 (d, J = 150.1 Hz, 4F), 
-61.8 (s, 3F). 13C NMR (CDCl3), : 172.2, 155.3, 149.5 (m), 139.8, 133.7, 127.2 (m), 127.0 (m), 
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124.8, 122.6, 121.3, 120.5, 119.2 (m), 118.5, 112.9, 75.1, 72.9, 22.8. MS [ESI, m/z]: 488.0 
[M+Na]. HPLC (method 1): retention time = 24.60 min. 
N-(3,5-(bis-trifluoromethyl)phenyl)-3-(4-pentafluorosulfanylphenoxy)-2-hydroxy-2-methyl-
propanamide  48a 
Purified by flash column chromatography eluting with n-hexane/EtOAc 100:0 v/v increasing to n-
hexane/EtOAc 50:50 v/v. Obtained in 54% yield as a thick transparent oil. 1H NMR (500 MHz, 
CDCl3) δ: 9.09 (s, 1H), 8.15 (s, 2H), 7.22-7.66 (m, 3H), 6.96 (d, J  = 9.1 Hz, 2H), 4.53 (d, J  = 9.1 
Hz, 1H), 4.08 (d, J  = 9.1 Hz, 1H), 3.40 (s, 1H), 1.65 (s, 3H). 19F NMR (CDCl3), : 85.36 (quintet, 
J = 151.1 Hz, 1F), 64.08 (d, J = 151.1 Hz, 4F), -62.9 (s, 1F). 13C NMR (126 MHz, CDCl3) δ: 172.1, 
159.5, 147.61 (t, J  = 18.0 Hz), 138.60, 132.53 (q, J  = 33.6 Hz), 127.83 (d, J  = 8.9 Hz), 123.02 
(q, J  = 272.8 Hz), 119.37 (d, J  = 3.2 Hz), 117.96 (d, J  = 7.6 Hz), 75.69, 72.71, 23.9; MS [ESI, 
m/z]: 534.05 [M+H], 556.05 [M+Na]. HPLC (method 1): retention time = 26.39 min. 
General method for the preparation of isothiocyanates 54-59 
A solution of NaHCO3 (0.κ2 g) in distilled water (4 mL) was stirred for 10 minutes and 
to it was added DCM (4 mL) followed by the different aniline 7-12 (2.4 mmol). The reaction 
mixture was cooled to 0 °C, thiophosgene (0.3 mL, 3.7 mmol) was added dropwise over 
10 minutes and the reaction was then stirred at r.t. overnight. The mixture was then diluted 
with DCM (20 mL), washed with brine (20 mL), the organic layer was dried over Na2SO4 
and concentrated to dryness. 
4-Isothiocyanato-3-(trifluoromethyl)benzonitrile 56 
Aniline 9 (4.λ mmol) was dissolved in λ mL toluene. Thiophosgene (10.67 mmol) was 
added dropwise and the mixture was stirred at 75 °C for five days. Obtained in λλ% yield 
as a brown wax. 1H NMR (CDCl3), μ 7.λ7 (d, J = 1.6 Hz, 1H), κ.κ6 (dd, J 1= κ.4 Hz, J 2= 
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1.6 Hz, 1H), 7.53 (d, J = κ.4 Hz, 1H). 1λF NMR (CDCl3), μ -63.12 (s, 3F). 13C NMR (CDCl3), 
μ 136.4, 130.λ (q, J = 5.5 Hz), 12λ.3, 122.7 (m), 120.5, 11λ.1 (m), 117.1, 116.6, 110.5. 
General method for the preparation of nitriles 61-64 
The different substituted anilines 10-12 and 60 (2.2 mmol) was added to a TMSCN 
solution (11.4 mmol) in acetone (10 mL). The mixture was heated at κ0 °C overnight. The 
reaction was then concentrated in vacuo and the residue was partitioned between water 
(15 mL) and ethyl acetate (15 mL). The water phase was re-extracted with ethyl acetate 
(2x15 mL). The combined organic layers were washed with brine (20 mL), dried over 
Na2SO4 and concentrated to dryness.  
2-Methyl-2-((4-(pentafluorosulfanyl)phenyl)amino)propanenitrile 61 
Obtained in 6λ% yield as white crystals. 1H NMR (CDCl3), μ 7.53 (d, J = λ.0 Hz, 2H), 
6.63 (d, J  = λ.0 Hz, 2H), 4.03 (bs, 1H), 1.62 (s, 6H). 1λF NMR (CDCl3), μ κ6.4 (quintet, J 
= 150.1 Hz, 1F), 64.6 (d, J = 150.1 Hz, 4F). 13C NMR (CDCl3), μ 146.0, 145.6 (p, J = 17.5 
Hz), 127.4 (p, J  = 4.κ Hz), 120.λ, 114.1, 4κ.0, 2κ.0. 
General method for the preparation of thiohydantoins 65-70 
A mixture of the different isothiocyanate 54-59 (1.01 mmol) and the different nitrile 61-
64 (00.κ4 mmol) in dry DMF (0.5 mL) was stirred at r.t. for 4κ h. To this mixture were 
added MeOH (10 mL) and 2N HCl (3 mL). The second mixture was refluxed for 6 h. After 
being cooled to r.t., the reaction mixture was poured into cold water (20 mL) and extracted 
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with ethyl acetate (20 mL). The organic layer was dried over Na2SO4 and concentrated 
under vacuum. The crude residue was purified by flash column chromatography. 
4-(4,4-dimethyl-5-oxo-2-thioxo-3-(4-pentafluorosulfanyl)phenyl)imidazolidin-1-yl)-2-
(trifluoromethyl)benzonitrile 67a 
Purified by flash column chromatography eluting with n-hexane/EtOAc 100μ0 v/v 
increasing to n-hexane/EtOAc 70μ30 v/v. Obtained in 25% yield as a white solid. 1H NMR 
(CDCl3), μ κ.01 (d, J = κ.3 Hz, 1H), 7.λλ-7.λ6 (m, 3H), 7.κ6 (dd, J1 = κ.3 Hz, J2 = 1.λ Hz, 
1H), 7.47 (d, J = κ.7 Hz, 2H), 1.64 (s, 6H). 1λF-NMR (CDCl3), μ κ2.6κ (quintet, J = 150.λ 
Hz, 1F), 62.λ4 (d, J = 150.λ Hz, 4F), -61.λλ (s, 3F). 13C NMR (CDCl3), μ 17λ.κ, 174.4, 
154.1 (m), 13κ.1, 136.κ, 135.2, 133.6 (q, J = 33.6 Hz), 132.1, 130.2, 127.κ (m), 127.0 (q, 
J = 4.λ Hz), 120.7 (q, J = 272.0), 110.5 (m), 66.5, 23.κ. MS [ESI, m/z]μ 516.0 [M+H], 53κ.0 
[M+Na]. HPLC (method 1)μ retention time = 24.77 min. 
Biological assays 
In vitro 2D monolayer assay  
This study was performed by CRO oncotest.  
Tumor Cell Lines 
The cell line panel used for assessing the novel inhibitors comprised four cell lines 
derived from human prostate cancersμ LNCaP, 22Rv1, VCaP, and DU145. Cell lines were 
routinely passaged once or twice weekly and maintained in culture for up to 20 passages. 
All cells were grown at 37°C in a humidified atmosphere with 5% CO2 in RPMI 1640 
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medium (25 mM HEPES, with L-glutamine, #FG13κ5, Biochrom, Berlin, Germany) 
supplemented with 10% (v/v) foetal calf serum (Sigma, Taufkirchen, Germany) and 
0.1 mg/mL gentamicin (Life Technologies, Karlsruhe, Germany).  
Compounds Handling 
Stock solutions for all inhibitors were prepared in DMSO at a concentration of 33 mM 
and aliquots of 200 µl were finally stored at -20°C. All compounds were well soluble at 
this concentration in DMSO and precipitation was not observed for any compound 
dissolved in 100% DMSO. Aliquots of the stock solution were thawed on the day of use 
and stored at room temperature prior to and during treatment. The subsequent dilutions 
were done with complete RPMI1640 cell culture medium. The DMSO stock solution was 
first diluted 1μ22 (corresponding to 4.5% v/v DMSO). Starting with this solution, serial 
dilutions in half-log steps with cell culture medium were done using an intermediate 
dilution plate. Finally, 10 µl taken from the intermediate dilution plate were transferred to 
140 µl / well of the cell culture plate. Thus, at the highest test concentration the DMSO 
stock was diluted 1μ330, corresponding to a maximum DMSO concentration of 0.3 % v/v 
in the assay. 
2D Cell Proliferation Assay 
A modified propidium iodide (PI) based monolayer assayκ1 was used to assess the anti-
cancer activity of the compounds. Briefly, cells were harvested from exponential phase 
cultures, counted and plated in λ6-well flat-bottom microtiter plates at a cell density of 
4,000 – 20,000 cells/well depending on the cell line’s growth rate. After a 24 h recovery 
period to allow the cells to resume exponential growth, 10 l of culture medium (six control 
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wells/plate) or culture medium with test compound were added. The compounds were 
applied in half-log increments at 10 concentrations (0.0032, 0.01, 0.032, 0.1, 0.32, 1, 3.2, 
10, 32, and 100 µM) in triplicate. After a total treatment period of λ6 h, cells were washed 
with 200 µl PBS to remove dead cells and debris. Then, 200 µl of a solution containing 
7 µg/ml propidium iodide (PI) and 0.1% (v/v) Triton X-100 was added. After an incubation 
period of 1-2 hours at room temperature, fluorescence (FU) was measured using the 
EnSpire Multimode Plate Reader (excitation = 530 nm, emission = 620 nm) to quantify 
the amount of attached viable cells. IC50 values were calculated by 4 parameter non-
linear curve fit using Oncotest Warehouse Software. For calculation of mean IC50 values 
the geometric mean was used. 
Androgen receptor agonist/antagonist assays 
The AR assay was performed by Invitrogen™ Life Technologies. 
The SelectScreen® Cell-Based Nuclear Receptor Profiling Service uses the 
GeneBLAzer® Betalactamase reporter technology. The GeneBLAzer® Validated Assays 
in the service are tested and documented to show a high level of performance.  
Compounds Handling 
 Test compounds were received by Cyprotex as a 10 µM solution, in 100% DMSO. The 
10 µM test compounds were serially diluted (10 point, 1/2-log increments) in 100% 
DMSO. 
Full Stim Control. 
33 
 
 The full stim control contained 0.1% DMSO, cells and a maximum concentration of the 
known stim (agonist, R1κκ1). In agonist mode, the full stim control is used to determine 
the upper end of the assay or 100% activation. In antagonist mode, the full stim control 
was used to determine the actual ECκ0 used in the assay, with the ECκ0 concentration 
chosen from previous agonist experiments. The control was run on each plate for each 
cell line. 
AR-Agonist Screen. 
  AR-UAS-bla GripTite™ 2λ3 cells were thawed and re-suspended in Assay Media 
(DMEM phenol red free, 2% CD-treated FBS, 0.1 mM NEAA, 1 mM Sodium Pyruvate, 
100 U/mL/100 g/mL Pen/Strep) to a concentration of 312,500 cells/mL. 4 L of a 10 µM 
of R1κκ1 (control agonist, EC50 = 0.322 nM) or the compounds under investigation (10 
µM concentration) were added to appropriate wells of a 3κ4-well Poly-D-Lysine assay 
plate. 32 L of cell suspension (10,000 cells) was added to each well. 4 L of assay media 
was added to all wells to bring the final assay volume to 40 L. The plate was incubated 
for 16-24 hours at 37 ºC /5% CO2 in a humidified incubator. κ L of 1 M substrate loading 
solution was added to each well and the plate incubated for 2 hours at room temperature. 
Fluorescence was then measured on a plate reader. 
AR-Antagonist Screen 
 Activated by R1κκ1μ AR-UAS-bla GripTite™ 2λ3 cells were thawed and prepared as 
described above for the Agonist Screen. 4 L of a 10X serial dilution of Cyproterone 
Acetate (control antagonist starting concentration, 3.160 nM) or compounds under 
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investigation were added to appropriate wells of a Poly-D-Lysine assay plate. 32 L of 
cell suspension was added to the wells and pre-incubated at 37ºC/5% CO2 in a humidified 
incubator with compounds and control antagonist titration for 30 minutes. 4 L of 10X 
control agonist R1κκ1 at the pre-determined ECκ0 concentration was added to wells 
containing the control antagonist or compounds. The plate was incubated for 16-24 hours 
at 37ºC/5% CO2 in a humidified incubator. κ L of 1 M of substrate loading solution was 
added to each well and the plate incubated for 2 hours at room temperature. Fluorescence 
was then measured on a plate reader. 
In vitro metabolic stability, plasma protein binding and cardiotoxicity studies 
All in vitro biological evaluations were performed by CYPROTEX.  
Microsomal Metabolic Stability 
Microsomes (final protein concentration 0.5 mg/mL), 0.1 M phosphate buffer pH 7.4 and 
test compound (final substrate concentration 3 M; final DMSO concentration 0.25 %) 
were pre-incubated at 37 °C prior to the addition of NADPH (final concentration 1 mM) to 
initiate the reaction. The final incubation volume is 50 L. A control incubation was 
included for each compound tested where 0.1 M phosphate buffer pH 7.4 was added 
instead of NADPH (minus NADPH). Two control compounds Dextromethorphan and 
Verapamil were included with each species. All incubations were performed singularly for 
each test compound. Each compound was incubated for 0, 5, 15, 30 and 45 min. The 
control (minus NADPH) was incubated for 45 min only. The reactions were then stopped 
by transferring 20 L of incubate to 60 L methanol at the appropriate time points. The 
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incubation plates were centrifuged at 2,500 rpm for 20 min at 4 °C to precipitate the 
protein, the sample supernatants were combined in cassettes of up to 4 compounds and 
samples analyzed by LC-MS/MS. 
 
Plasma protein binding 
Test compound solutions (final concentration 5 M) were prepared in both 100 % species-
specific plasma and buffer (pH 7.4). The plasma solution was added to one side of the 
membrane in an equilibrium dialysis system while the buffer solution was added to the 
other side. The system was allowed to reach equilibrium at 37 °C. Compound 
concentration on both sides of the membrane was measured by LC-MS/MS and the 
fraction of unbound compound was calculated. The extent of binding is reported as % 
mean bounded.  
hERG Channel Inhibition (IC50 Determination)  
Chinese hamster ovary (CHO) cells (cell-line obtained from Cytomyx, UK) expressing 
the hERG potassium channel were dispensed into 3κ4-well planar arrays and hERG tail-
currents measured by whole-cell voltage-clamping. The experiments were performed on 
an IonWorksTM HT instrument (Molecular Devices Corporation), which automatically 
performs electrophysiology measurements in 4κ single cells simultaneously in a 
specialised 3κ4-well plate (PatchPlateTM). All cell suspensions, buffers and test 
compound solutions were at room temperature during the experiment. A single-cell 
suspension was prepared in extracellular solution (Dulbecco’s phosphate buffered saline 
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with calcium and magnesium pH 7 - 7.2) and aliquots added automatically to each well of 
a PatchPlateTM. The resistance of each seal was measured via a common ground-
electrode in the intracellular compartment and individual electrodes placed into each of 
the upper wells. 
Electrical access to the cells was then achieved by circulating a perforating agent, 
amphotericin, underneath the PatchPlateTM and then measuring the pre-compound 
hERG current. An electrode was positioned in the extracellular compartment and a 
holding potential of -κ0 mV applied for 15 sec. The hERG channels were then activated 
by applying a depolarising step to +40 mV for 5 sec and then clamped at -50 mV for 4 
sec to elicit the hERG tail current, before returning to -κ0 mV for 0.3 s. Test compound 
solutions (prepared by diluting 10 mM DMSO solutions into extracellular buffer to a  final 
concentration of 25 M, final DMSO concentration 0.25 %), were then added 
automatically to the upper wells of the PatchPlateTM from a λ6-well microtitre plate. The 
test compounds were left in contact with the cells for 300 sec before recording currents 
using the same voltage-step protocol as in the pre-compound scan. Quinidine, an 
established hERG inhibitor, is included as a positive control and buffer containing 0.25 % 
DMSO is included as a negative control. Each concentration is tested in 4 replicate wells 
on the PatchPlateTM. 
In vivo efficacy assay. 
Male immunodeficient NMRI nu/nu mice from Harlan were used. The animals were 
delivered at the age of four to six weeks and used for implantation after at least one week 
of quarantine. All experiments are approved by the local authorities and are conducted 
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according to the guidelines of the German Animal Welfare Act (Tierschutzgesetz). For 
antitumor activity experiments mice were injected in the hind flank with tissue culture 
22Rv1 cells patient derived. Animals and tumour implants were monitored daily until the 
maximum number of implants show clear signs of beginning solid tumour growth. When 
the tumor mass had reached κ0 – 200 mm3 the mice were randomized into groups and 
therapy with the selected inhibitor and docetaxel were performed for 4 weeks. Treatment 
with the investigational compound was given as 16-1κ daily intraperitoneal (i.p.) doses, 
whereas docetaxel was given as three weekly intravenous (i.v.) treatments.The 
antitumoral efficacy of 48a was then evaluated.  Vehicle for 48a and control vehicle was 
10% Ethanol 10% Cremophor EL 5% dextrose. Control mice were treated with vehicle for 
the same treatment period. The absolute tumor volumes (ATVs) were determined by two-
dimensional measurement with a caliper on the day of randomization and then twice 
weekly. Tumor volumes are calculated according to the formulaμ Tumor volume = (a x b2) 
x 0.5 where a represents the largest and b the perpendicular tumor diameter of the tumor 
representing an idealized ellipsoid. Statistical significance of anti-tumor efficacy was 
evaluated on the days where the minimum T/C values are reached in the relevant test 
groups (day 14). Statistical analysis was only carried out if at least 50% of the initially 
randomized animals in a relevant group are still alive.  
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